Viatris Inc.

Equities

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
10.41 USD -1.14% Intraday chart for Viatris Inc. -5.19% -3.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Viatris Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing MT
UBS Trims Viatris Price Target to $12 From $13, Maintains Neutral Rating MT
Transcript : Viatris Inc., Q1 2024 Earnings Call, May 09, 2024
Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024 CI
Viatris Inc. Revises Earnings Guidance for the Year 2024 CI
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced MT
(VTRS) VIATRIS Forecasts Fiscal Year 2024 Revenue Range $14.98B - $15.48B MT
Earnings Flash (VTRS) VIATRIS Posts Q1 Revenue $3.66B, vs. Street Est of $3.69B MT
Earnings Flash (VTRS) VIATRIS Reports Q1 EPS $0.67, vs. Street Est of $0.67 MT
Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
China trade heats up, UK rates in view RE
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal MT
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada MT
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer CI
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc CI
UK's Theramex sees no impact to HRT products supply after CMA probe RE
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal MT
UK watchdog says Theramex-Viatris deal raises competition concerns RE
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review MT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent RE
Chart Viatris Inc.
More charts
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
10.41 USD
Average target price
12.33 USD
Spread / Average Target
+18.47%
Consensus
  1. Stock Market
  2. Equities
  3. VTRS Stock
  4. News Viatris Inc.
  5. Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says